Axonal swellings predict the degeneration of epidermal nerve fibers in painful neuropathies by G. LAURIA PINTER et al.
Axonal swellings predict the degeneration
of epidermal nerve fibers in
painful neuropathies
G. Lauria, MD; M. Morbin, MD, PhD; R. Lombardi, PhD; M. Borgna, PhD; G. Mazzoleni, PhD;
A. Sghirlanzoni, MD; and D. Pareyson, MD
Abstract—Objective: To correlate the density of swellings in intraepidermal nerve fibers (IENF) with the longitudinal
measurement of the epidermal innervation density in patients with painful neuropathy and to assess the predictive value
of IENF swelling to progression of neuropathy. Methods: Fifteen patients with persistent pain in the feet underwent
neurologic examination, nerve conduction studies, quantitative sensory examination, and skin biopsies at proximal thigh
and distal leg. In all patients and in 15 healthy subjects, IENF density and swelling ratio (no. swellings/no. IENF) were
quantified at distal leg. Follow-up study, including IENF density and swelling ratio quantification, was performed a mean
of 19.2 months later. Double staining confocal microscope studies using anti-human protein-gene-product 9.5, anti-tubule,
anti-neurofilament, and anti-synaptophysin antibodies were performed to assess specific accumulation within swellings.
Ultrastructural investigation of IENF was also carried out. Results: Patients with neuropathy had lower density of IENF
and higher swelling ratio than healthy subjects (p  0.01) at distal leg. At follow-up, patients showed a parallel decrease
in both IENF density (p  0.02) and swelling ratio (p  0.002). However, swelling ratio remained higher (p  0.03) than in
controls. Progression of neuropathy was confirmed by the decay in sural nerve sensory nerve action potential amplitude.
Double immunostaining studies suggest accumulation of tubules and ubiquitin-associated proteins within swellings.
Swollen and vacuolated IENF were identified in patients with neuropathy by conventional and immuno-electron micros-
copy. Conclusions: Increased swelling ratio predicted the decrease in IENF density in patients with painful neuropathy.
Its quantification could support earlier diagnosis of sensory axonopathy.
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Skin biopsy is used in the evaluation of painful neu-
ropathies, to assess the predominant, or selective,
impairment of unmyelinated sensory axons. The loss
of intraepidermal nerve fibers (IENF), which are so-
matic axons, correlated with the presence and the
severity of the neuropathy.1–11 However, further cri-
teria other than the simple count of IENF might be
taken into account to increase the diagnostic yield of
skin biopsy, mainly in patients with minimal or no
evidence of neuropathy. Different studies1,2,5,9 showed
that in some patients, despite persisting positive
sensory symptoms, IENF density at distal leg was
within normal values. Patients with painful neurop-
athy frequently showed morphologic modifications of
cutaneous nerves, such as periodic swellings of
IENF, which were commonly considered degenera-
tive changes.2-5 Axonal swellings can occur in re-
sponse to damage to the cytoskeleton and the
transport systems12,13 and could precede the loss of
IENF.14,15 In human painful neuropathies, they were
never quantified and correlated to the course of the
disease.
We assessed the swelling ratio of IENF (no. swell-
ings/no. IENF) at distal leg in 15 patients with pain-
ful neuropathy and correlated it with the epidermal
innervation density in a follow-up study. Results
suggested that quantification of IENF swellings
could strengthen the role of skin biopsy in the early
diagnosis of sensory neuropathies.
Patients and methods. Fifteen patients (seven women; age 31
to 68 years) referred for persisting painful symptoms at the feet
were examined. They underwent neurologic examination, nerve
conduction studies (NCS), and quantitative sensory examination
(QST) using the Computed-Assisted Sensory Examinator device
(W.R. Medical Electronics Co., Stillwater, MN). Skin biopsies were
taken at proximal thigh and distal leg in all patients and in 15
age-matched healthy subjects (9 women). Follow-up was carried
out a mean of 19.2 months later (range 12 to 28 months). All
patients and controls gave their informed consent to the study.
IENF density and swelling ratio quantification. Skin biopsies
(3-mm punch; Stiefel Laboratories Ltd., Sligo, Ireland) were per-
formed after local anesthesia with 2% lidocaine. Follow-up biop-
sies were taken from the same lower limb, close to the former one.
Specimens were fixed in 2% paraformaldehyde-lysine-periodate
for 24 hours at 4 °C, cryoprotected overnight, and serially cut with
a freezing microtome to obtain 50-m sections. Three sections
were randomly selected from each biopsy and immunostained
with polyclonal anti-human protein-gene-product 9.5 (PGP; Bio-
genesis Ltd., Poole, UK) as described.3 Two observers (G.L. and
M.B.), blinded to site and diagnosis, counted the total number of
IENF in each section under a light microscope at high magnifica-
tion, with the assistance of a microscope-mounted video camera.
Individual fibers were counted as they crossed the dermal-
From the Department of Clinical Neuroscience (Drs. Lauria, Lombardi, Borgna, Sghirlanzoni, and Pareyson) and Section of Neuropathology (Drs. Morbin and
Mazzoleni), National Neurological Institute “Carlo Besta,” Milan, Italy.
Received December 4, 2002. Accepted in final form March 9, 2003.
Address correspondence and reprint requests to Dr. Giuseppe Lauria, Department of Clinical Neuroscience, National Neurological Institute “Carlo Besta,”
via Celoria, 11, 20133, Milan, Italy; e-mail: g_lauria@libero.it
Copyright © 2003 by AAN Enterprises, Inc. 631
epidermal junction; secondary branching within the epidermis
was excluded from the quantification. The length of the epidermis
was measured using a computerized system (Microscience Inc.,
Seattle, WA) and the linear density of IENF (IENF/mm) obtained.
Swelling ratio of IENF (no. of swellings/no. of IENF) at distal
leg was calculated at both first examination and follow-up in the
same three sections in which IENF density was previously quan-
tified by the same blinded observers. All IENF swellings with a
diameter above 1.5 m were counted, whereas enlargements be-
low this value were considered normal axonal varicosity and ex-
cluded from the quantification. Terminal enlargements of IENF
were a priori excluded from quantification. A 1.5-m–length
marker was constantly kept on the upper right corner of the
monitor to check the diameter of swellings. Individual IENF den-
sity and swelling ratio were compared using the two-tailed Stu-
dent t-test. Interobserved agreement was assessed by the
Spearman correlation coefficient.
Confocal microscope studies. Double immunofluorescence
studies were performed using polyclonal anti-PGP antibodies and
each of the following monoclonal antibodies: anti-unique -tubulin
(TuJ1, Berkley Antibody Company, Richmond, CA), anti-
microtubule-associated protein-1B (MAP-1B, Roche Diagnostics
Corp., Indianapolis, IN), anti-neurofilament (NF, Dako, Glostrup,
Denmark), anti-phosphorylated neurofilament (SMI 312, Stern-
berger Monoclonals Incorporated, Baltimore, MD), and anti-
synaptophysin (Dako, Glostrup, Denmark).
Sections were preincubated for 1 hour in 0.1 M phosphate
buffered saline (PBS) containing 1% bovine serum albumin (BSA,
Sigma Chemical Co., St. Louis, MO) and 0.4% Triton X-100. Pri-
mary antisera (PGP 1:500, TuJ1 1:1000, MAP-1B 1:100, NF 1:100,
SMI 312 1:200, synaptophysin 1:10) were added with 0.1% BSA in
0.1 M PBS and incubated for 2 nights at 4 °C. Cy2-conjugated
immunoglobulin G (IgG) goat antirabbit (HL) (AffiniPure, Jack-
son Immuno Research Laboratories, Inc., West Grove, PA) was
used as secondary antibody for polyclonal PGP. Biotinylated horse
antimouse IgG (HL) (Vector Laboratories, Inc., Burlingame, CA)
was used as secondary antibody for monoclonal TuJ1, MAP-1B,
NF, SMI 312, and synaptophysin, followed by amplification with
rhodamine Red-X-conjugated streptavidin (Jackson Immuno Re-
search Laboratories, Inc.). Samples were viewed using appropri-
ate filters with a MicroRadiance 2000 Confocal Imaging System
(Bio-Rad, Hemel Hempstead, UK) and a Nikon 600 fluorescence
microscope (Melville, NY). Each image was collected in successive
frames of 0.5 to 1 m apart at 40 magnification and was inte-
grated by a computerized system (LaserSharp 2000; Bio-Rad).
Conventional electron microscope study. Specimens were
fixed in 2.5% EM grade glutaraldehyde (Fluka Chemie, AG Buchs,
CH) in 0.05 M PBS at pH 7.4, postfixed in 1% osmium tetroxide
(Electron Microscopy Sciences, Fort Washington, PA) in 0.05 M
PBS, dehydrated in graded acetone, and embedded in Spurr
(EMS). Thin sections (500 Å thick) of selected areas including
dermal-epidermal junction were harvest on 200 mesh copper grids
(EMS) stained with lead citrate and uranyl acetate and viewed
with a Zeiss EM 109 electron microscope.
Immuno-electron microscope study. Specimens were fixed in
0.04% (w/v) paraformaldehyde (BDH Italia, Milan, Italy) plus 1%
glutaraldehyde for 3 hours and in 0.6% glutaraldehyde overnight,
dehydrated in graded acetone, and embedded in Spurr. Thin sec-
tions of selected areas including dermal-epidermal junction were
collected on formvar-carbon coated 200 mesh nickel grids (EMS)
and processed using the following protocol: 1 hour incubation in
1% Na periodate, dip in 0.05 M glycine pH 4.0 (Sigma, St Louis,
MO), and cover with Aurion-BSA incubation buffer (Aurion,
Wageningen, the Netherlands) for 30 minutes. Polyclonal anti-
PGP antibody was diluted 1:100 in the same buffer and placed on
grids overnight at 4 °C. Following wash in Aurion-BSA, grids were
incubated with goat antirabbit gold (GAR-10) conjugated antibody
(Aurion) diluted 1:20 in PBS for 3 hours at room temperature.
Sections were fixed in 1% glutaraldehyde, postfixed in 1% OsO4,
and counterstained with uranyl acetate and lead citrate.
Results. Clinical findings. All patients had burning
feet or pain bilaterally involving distally the lower extrem-














ratio, DlPth Dl Pth Dl Pth Dl
1 Diabetes  12.7 6.0 0.60 11.5 3.0 0.26 27.0 12.5 0.29
2 Diabetes  26.0 5.2 0.83 22.0 3.9 0.72 21.5 9.0 0.31
3 Diabetes  20.7 4.7 0.54 18.0 3.6 0.51 32.6 14.2 0.26
4 Diabetes  15.0 5.9 0.55 13.5 4.1 0.32 28.5 10.7 0.23
5 Diabetes  27.9 11.4 0.62 23.4 6.8 0.50 25.1 16.4 0.22
6 Diabetes  12.7 5.0 0.43 10.5 0.0 0.00 13.5 15.9 0.13
7 Idiopathic  13.8 5.8 0.43 12.5 3.2 0.27 25.0 12.7 0.21
8 Idiopathic  18.9 6.6 0.57 17.7 3.4 0.48 18.2 10.4 0.16
9 AIDS  14.0 6.2 0.60 12.1 2.8 0.40 20.2 15.2 0.43
10 Taxol  13.1 8.3 0.54 12.3 5.4 0.36 15.6 11.8 0.30
11 Idiopathic  10.1 3.2 0.61 10.0 2.3 0.59 22.0 18.0 0.56
12 Idiopathic  22.0 18.0 0.55 19.6 13.0 0.45 25.2 16.1 0.46
13 Idiopathic  25.5 13.5 0.68 21.1 6.4 0.59 21.1 19.1 0.42
14 Idiopathic  30.4 17.3 0.64 28.0 9.0 0.38 21.9 18.2 0.22
15 Idiopathic  13.5 8.9 0.72 12.6 6.2 0.52 21.9 15.4 0.32
Mean (SD) 18.4 (6.5) 8.4 (4.6) 0.59 (0.1) 16.3 (5.5) 4.9 (3.1) 0.42 (0.2) 22.6 (4.8) 14.4 (3.0) 0.30 (0.12)
Neuropathic signs included reduced or absent Achilles tendon reflexes and reduced light-touch and pinprick sensation at distal lower
extremities.
IENF  intraepidermal nerve fibers; Pth  proximal thigh; Dl  distal leg; Swelling ratio  no. swellings/no. IENF (mean of three val-
ues calculated at distal leg).
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ities for a mean of 2.5 years (range 0.5 to 4 years). Neurop-
athy was related to diabetes in six patients, to AIDS in one
patient, and to Taxol toxicity in one patient; it was idio-
pathic in seven patients. At the first evaluation, nine pa-
tients showed reduced or absent Achilles tendon reflexes,
decreased light touch and pinprick sensation at distal
lower extremities, and mean sural sensory nerve action
potential (SNAP) amplitude of 6.2  3.5 V. The other six
patients (five idiopathic and Taxol-associated neuropathy)
had normal results on neurologic examination and higher
(p  0.01) sural SNAP amplitude (15.9  5.5 V). Results
of strength and motor nerve conduction studies were nor-
mal in all patients. Vibratory threshold was increased
(	99th percentile) in all except one patient who had 94th
percentile, whereas cooling threshold was increased in
only five patients.
At follow-up, all patients had a worsening of symptoms
and showed a decrease (p  0.04) in sural SNAP amplitude
(6.7  6.6 V). This was more evident in patients who had
signs of neuropathy at the first observation (1.9  3.3 V)
than in those without (9.9  6.5 V). Vibratory threshold
was increased in all patients, whereas cooling threshold
was 	99th percentile in eight of them. In two of the six
patients with normal clinical picture at baseline (one idio-
pathic and Taxol-associated neuropathy), reduced Achilles
tendon reflexes and slight decrease of light touch and pin-
prick sensation at distal lower extremities were observed.
IENF density quantification. At the first examination,
IENF density at distal leg was lower (p  0.01) in patients
than in healthy subjects (8.4  4.6/mm and 14.4  3.0/
mm), whereas it did not differ at proximal thigh (18.4 
6.5/mm and 22.6  4.8/mm; p  0.05). Patients with signs
of neuropathy showed a lower IENF density at distal leg
than those without (6.3  2.0/mm and 11.5  5.7/mm; p 
0.04). At follow-up, patients showed a decrease in IENF
density also at proximal thigh, which became lower than in
healthy subjects. Compared with baseline, density at distal
leg was lower (4.9  3.1/mm; p  0.02), whereas the differ-
ence was not significant at proximal thigh (16.3  5.5/mm;
p  0.3) (table).
Swelling ratio quantification. Swelling ratio of IENF
at distal leg was higher (p  0.001) both in patients with
neuropathic signs (0.57  0.12) and in those without (0.62
 0.07) than in healthy subjects (0.30  0.12). Moreover, it
was also higher in Patients 12 through 15, who showed
normal IENF density at the first examination (see the
table). At follow-up, patients showed a lower swelling ratio
(0.42  0.17; p  0.002) than that found at the first obser-
vation, although the value remained higher (p  0.03)
than in controls (figure 1). Spearman correlation coeffi-
cient was 0.88 (p  0.01), indicating a high inter-observed
agreement in swelling quantification.
Morphologic findings. In patients, the diameter of
IENF swellings ranged between 1.8 and 5.4 m. Some
swellings showed a nonhomogeneous PGP labeling,
whereas others appeared partly or completely vacuolated
(figure 2). In healthy subjects, IENF often showed fine
varicosities and club-like endings.
In both healthy subjects and patients, double staining con-
focal microscope studies disclosed that both TuJ1 and
Figure 1. Relationship between intraepidermal nerve fi-
ber (IENF) density and swelling ratio at the distal leg in
patients with painful neuropathies at baseline and
follow-up and in age-matched healthy subjects.
Figure 2. (A) Light microscope protein-gene-product 9.5
(PGP) immunostaining shows an intraepidermal nerve
fiber (IENF) with multiple swellings, which appeared
partly or completely vacuolated. (B) PGP immuno-electron
microscope image shows a swollen IENF with amorphous
debris and several vacuoles. Note the 10-nm gold particles
within the structure.
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MAP-1B diffusely colocalized with PGP in IENF, whereas NF
and SMI 321 were expressed in fewer epidermal axons. Sim-
ilarly, almost all PGP-positive swellings presented immuno-
reactivity to TuJ1, whereas fewer showed NF labeling.
Swellings did not present immunoreactivity to synaptophy-
sin, which was observed only in some dermal nerve fibers
(figure 3). Other PGP-positive processes were identified
within the epidermis, including faint staining of Langerhans
cell processes, which, however, showed intense TuJ1
staining.
Single membrane-bound profiles containing few identi-
fiable organelles, such as mitochondria, vesicles, and tubu-
lar structures of 10 to 20 nm, likely representing axonal
profiles, were observed within all the epidermal vital lay-
ers in both controls and patients with neuropathy by con-
ventional electron microscopy. However, only these profiles
showed PGP immunoreactivity on immuno-electron mi-
croscopy. In patients with neuropathy, swollen axons with
granular disintegration of the cytoskeleton and vacuoles
could be observed (see figure 2).
Discussion. The availability of antibodies against
the panaxonal marker PGP allowed demonstration
and quantification of the extensive innervation of the
Figure 3. Confocal microscope double
staining colocalization studies (40 ob-
jective) between protein-gene-product
9.5 (PGP) (A, C, E, and G) and
-tubulin (B), microtubule-associated
protein-1B (MAP-1B, D), neurofilament
(F), and anti-synaptophysin (H) in skin
biopsies taken at the distal leg in pa-
tients with neuropathy. Note the colo-
calization between PGP and MAP-1B
(D) through the length of the fibers, but
not within the swellings. Synaptophysin
(H) did not stain intraepidermal nerve
fiber swellings.
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epidermis by sensory unmyelinated axons.16 Several
studies, including the current one, demonstrated the
correlation between the decrease in IENF density
and the severity of neuropathy.1-10
We aimed at strengthening the role of skin biopsy
in the diagnosis of painful neuropathies by quantify-
ing the swelling ratio of IENF at distal leg, beside
the epidermal innervation density. In fact, periodic
swellings of IENF, which were considered degenera-
tive changes,17 were never before quantified or corre-
lated to the course of the neuropathy. This could be
useful in identifying early sensory axonopathy in pa-
tients with persistent painful symptoms at the feet,
particularly in those showing normal IENF count.
We found that swelling ratio of IENF at distal leg
was significantly higher in patients with neuropathy
than in healthy subjects, indicating an increased
number of axons with likely degenerative changes.
This was also observed in four patients with persis-
tent burning feet and normal IENF density at the
first examination (Patients 12 through 15). The hy-
pothesis that diffuse swellings might represent early
evidence of IENF axonopathy was supported by the
results of follow-up examination. In fact, all patients
showed a decrease in epidermal innervation density
at distal leg (see the table), suggesting that swellings
preceded the eventual loss of IENF. Moreover, at
follow-up we found a decrease in swelling ratio,
which appeared to have a linear relationship with
the decrease in IENF density, although the value
remained significantly higher than that in healthy
subjects (see figure 1). Progression of neuropathy
was also confirmed by the decrease in sural SNAP
amplitude at follow-up evaluation.
These findings appeared in keeping with the re-
sults of recent experimental studies that demon-
strated that swellings of IENF occurred very early
after sciatic nerve axotomy14 and acrylamide intoxi-
cation,15 and predicted their disappearance. Several
factors, including toxic agents, diabetes, and ische-
mia, can influence the caliber of axons leading to
failure in the axonal transport systems and derange-
ment of the cytoskeleton.12 Accumulation of neuro-
filaments and microtubules, followed by their
degradation into amorphous debris, can result in the
formation of axonal swellings.13,14,18,19
In healthy subjects, IENF typically showed tiny var-
icosity, which likely reflected the uneven distribution of
cytoskeletal components. Normal IENF often ended
with a single club-like enlargement, as previously de-
scribed.6 For this reason, we excluded a priori terminal
enlargements from swelling ratio quantification. In pa-
tients with neuropathy, the diameter of swellings was
two- to fivefold that of normal axons. They showed
intense, although not always homogeneous, PGP stain-
ing, and could be partly or completely vacuolated, sug-
gesting different stages of axonal degeneration (see
figure 2). Fragmented and discontinuous dermal nerve
bundles were also usually observed in patients with
neuropathy. Confocal double staining studies were per-
formed to identify accumulation of specific cytoskeletal
components within IENF swellings. In healthy sub-
jects, almost all IENF coexpressed PGP, TuJ1, and
MAP-1B, whereas fewer IENF showed NF labeling.
Similarly, in patients with neuropathy, PGP and TuJ1
colocalized in most swollen IENF, whereas fewer axons
showed immunoreactivity to NF. These findings sug-
gested that tubules were the main component of IENF
cytoskeleton and that they accumulated with
ubiquitin-associated proteins within swellings. Con-
versely, vesicles did not appear to accumulate within
swellings, as suggested by the absence of immunoreac-
tivity to synaptophysin (see figure 3).
Langerhans cell processes showed faint PGP
staining and intense TuJ1 labeling. Moreover, epi-
dermal axons are single membrane bound, because
Schwann cell ensheathment ends at the dermal-
epidermal junction.3 These were major limitations
for ultrastructural investigation of nerve fibers
within the epidermis, which required extensive eval-
uation of several sections. However, axon profiles
were detected within all the epidermal layers in con-
trols and patients with neuropathy. They were be-
tween keratinocytes or in membrane apposition with
them, as previously shown by other authors.20,21 In
swollen IENF, axoplasm was mainly replaced by amor-
phous debris. In patients with neuropathy, several
IENF showed one or more vacuoles, which likely corre-
sponded to the areas of nonhomogeneous PGP staining
observed under light microscopy (see figure 2).
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CME Temporal lobe tumoral epilepsy
Characteristics and predictors of surgical outcome
Megdad M. Zaatreh, MD; Katrina S. Firlik, MD; Dennis D. Spencer, MD; and Susan S. Spencer, MD
Abstract—Objective: To review the clinical and neurophysiologic features and surgical outcome in patients with intracta-
ble temporal lobe tumoral epilepsy. Methods: Patients with intractable temporal lobe epilepsy who underwent resection of
temporal lobe tumors, confirmed by surgical pathology, seen between 1985 and 2000 at Yale University School of Medicine
Epilepsy Center, were selected. Medical records were reviewed for age at diagnosis, age at onset of seizures, delay between
seizure onset and tumor diagnosis, types and frequencies of seizures, EEG results, use of anticonvulsants, extent of
surgery, and pathologic diagnosis. Results: Sixty-eight patients were identified, 94.1% of them with low-grade tumors.
Complex partial seizure was the most common seizure type. All patients underwent at least one surgical procedure with
average follow-up of 9 years after surgical intervention. Eighty-seven percent of patients had significant postoperative
seizure improvement (Engel’s classes I and II). Gross total tumor resection predicted postoperative seizure freedom (p 
0.002), whereas patients with early surgical intervention, auras, and simple partial seizures had a tendency toward better
seizure outcome. Conclusions: Long-term follow-up of patients with intractable temporal lobe tumoral epilepsy suggests
good response of seizures to surgery, which is unrelated to age at diagnosis, EEG, or pathology. Extent of tumor resection
was significantly predictive of outcome, whereas early intervention and presence of simple partial seizures showed trends
as predictive factors.
NEUROLOGY 2003;61:636–641
Chronic epilepsy due to brain tumors has been de-
scribed since the nineteenth century,1 and multiple
studies have addressed various aspects of tumoral
epilepsy.2-4 The remarkable advances in neuroimag-
ing techniques now allow detection of previously un-
known tumors, so new scrutiny is warranted.5
Pathophysiology of tumoral epilepsy is poorly under-
stood and may be related to biochemical, anatomic,
and physiologic changes, especially in the peritu-
moral tissue, which seems to be the major source of
seizure generation.6-8 The best approach to manage-
ment of tumoral epilepsy is controversial in some
cases, although resective surgery is often advocated.9
Temporal lobe resection is the most common sur-
gical treatment in refractory epilepsy, with robust
evidence supporting the safety and efficacy of this
procedure.10,11 Numerous publications reported pre-
dictors of surgical outcomes and long-term prognosis
in patients with temporal lobe epilepsy, though in
most studies, emphasis was placed on patients with
mesial temporal sclerosis, with few temporal neo-
plasms represented.11,12 Yet most chronic epilepsy as-
sociated with tumors is also temporal in origin. Few
studies addressed the clinical, electrographic, and
surgical features of temporal lobe epilepsy specifi-
cally associated with tumor.13,14 We report our expe-
rience with temporal lobe tumoral epilepsy with
special attention to the clinical aspects, presurgical
diagnostic workup, and long-term surgical outcomes.
Methods. Patient selection. Medical records of all patients
with medically intractable partial epilepsy who underwent resec-
tion of temporal lobe tumors (confirmed by surgical pathology)
seen between January 1985 and July 2000 at Yale University
School of Medicine Epilepsy Center were reviewed. Data collected
included age at tumor diagnosis, age at onset of seizures, delay
between seizure onset and tumor diagnosis, other seizure risk
factors, types and frequencies of seizures, EEG results, use of
anticonvulsants, extent of surgery, and pathologic diagnosis. Pa-
tients with 2 years follow-up, incomplete data, neurocutaneous
disorders, or prior brain surgery were excluded.
Patient evaluation. All patients were diagnosed using preop-
erative high-resolution brain MRI. Prior to surgery, identification
of the epileptic zone was attempted using most or all of the follow-
ing: clinical seizure semiology, scalp interictal EEG localization,
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